Announcements
- NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month
- New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
- NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
- Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network
- Neuronetics Launches Latest Evolution in its TrakStar® Patient Data Management System
- NeuroStar TMS Patient Access Expands Through Lucet Health Policy Update
- Neuronetics Receives 510(k) Clearance for NeuroSite™ Coil Placement Accessory
- NeuroStar TMS Receives Expanded Regulatory Approval in Japan
- NeuroStar Elevates Depression Treatment with Cutting-Edge Technology Advancements
- Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy Coverage
More ▼
Key statistics
On Friday, Neuronetics Inc (NRC:DUS) closed at 3.16, 1.94% above its post-IPO low of 3.10, set on Apr 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.16 |
---|---|
High | 3.16 |
Low | 3.16 |
Bid | 3.47 |
Offer | 3.59 |
Previous close | 3.22 |
Average volume | 0.00 |
---|---|
Shares outstanding | 29.97m |
Free float | 28.08m |
P/E (TTM) | -- |
Market cap | 114.20m USD |
EPS (TTM) | -1.06 USD |
Data delayed at least 15 minutes, as of May 03 2024 07:13 BST.
More ▼